OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays

<b> </b>Differences in botulinum neurotoxin manufacturing, formulation, and potency evaluation can impact dose and biological activity, which ultimately affect duration of action. The potency of different labeled vials of incobotulinumtoxinA (Xeomin<sup>®</sup>; 50 U, 100 U,...

Full description

Bibliographic Details
Main Authors: David Rupp, Greg Nicholson, David Canty, Joanne Wang, Catherine Rhéaume, Linh Le, Lance E. Steward, Mark Washburn, Birgitte P. Jacky, Ron S. Broide, Wolfgang G. Philipp-Dormston, Mitchell F. Brin, Amy Brideau-Andersen
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Toxins
Subjects:
BOTOX
cell-based potency assay (CBPA)
compound muscle action potential (cMAP) electrophysiology assay
digit abduction score (DAS) assay
dose conversion
interchangeability
Online Access:https://www.mdpi.com/2072-6651/12/6/393

Internet

https://www.mdpi.com/2072-6651/12/6/393

Similar Items